Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

BACKGROUND: For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to prolong progression free survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huijts, Charlotte M, Santegoets, Saskia J, van den Eertwegh, Alfons J, Pijpers, Laura S, Haanen, John B, de Gruijl, Tanja D, Verheul, Henk M, van der Vliet, Hans J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305518/
https://www.ncbi.nlm.nih.gov/pubmed/22129044
http://dx.doi.org/10.1186/1471-2407-11-505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305518/
https://www.ncbi.nlm.nih.gov/pubmed/22129044
http://dx.doi.org/10.1186/1471-2407-11-505

Ejemplares similares